Medpacto takes part in BIO 2023… will actively engage in discussions regarding the commercialization of its pipelines, exploring opportunities for out-licensing
May 31, 2023
Enhancing collaboration with global pharmaceutical companies, including forging partnerships for the development of pipelines targeting bone diseases.
[2023-05-31]
On May 31st, Medpacto (CEO Kim Seong-jin), a genome-based drug discovery and a clinical-stage biotechnology company announced its participation in one of the world's largest biopharmaceutical conventions, the 'BIO 2023 International Convention' (Bio USA).
Bio USA holds a prominent position as the preeminent assembly fostering collaboration and partnership within the pharmaceutical and biotechnology sectors. Alongside the esteemed JP Morgan Healthcare Conference and Bio Europe, it stands as a pinnacle event in the industry. Themed as 'Stand up for Science' for this year's edition, Bio USA anticipates the active engagement of 5,000 companies hailing from 60 countries worldwide.
During this esteemed event, MedPacto has strategic plans to actively participate in discussions with global pharmaceutical companies. The primary objective is to explore opportunities for joint development and out-licensing of its pivotal pipelines, with a specific emphasis on novel candidates for the treatment of bone diseases.
Having already taken part in the esteemed 'JP Morgan Healthcare Conference' held in San Francisco, USA, earlier this year, as well as the notable 'BIO Europe Spring' held in Basel, Switzerland in April, MedPacto is actively advancing its efforts towards the commercialization of its pipeline.
“We are to engage in partnership meetings with global pharmaceutical companies exploring opportunities for joint development and out-licensing our significant pipelines. This includes our new candidate for the treatment of bone diseases.” stated MedPacto representative